- Home
- IMRN vs PHIO Comparison
IMRN vs PHIO Comparison
Compare IMRN & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- PHIO
- Stock Information
- Founded
- IMRN 1994
- PHIO 2011
- Country
- IMRN Australia
- PHIO United States
- Employees
- IMRN N/A
- PHIO N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- PHIO Health Care
- Exchange
- IMRN Nasdaq
- PHIO Nasdaq
- Market Cap
- IMRN 9.2M
- PHIO 8.6M
- IPO Year
- IMRN N/A
- PHIO N/A
- Fundamental
- Price
- IMRN $1.88
- PHIO $2.16
- Analyst Decision
- IMRN Strong Buy
- PHIO Strong Buy
- Analyst Count
- IMRN 1
- PHIO 2
- Target Price
- IMRN $5.00
- PHIO $9.00
- AVG Volume (30 Days)
- IMRN 25.2K
- PHIO 703.0K
- Earning Date
- IMRN 07-07-2025
- PHIO 08-13-2025
- Dividend Yield
- IMRN N/A
- PHIO N/A
- EPS Growth
- IMRN N/A
- PHIO N/A
- EPS
- IMRN N/A
- PHIO N/A
- Revenue
- IMRN $4,048,286.00
- PHIO N/A
- Revenue This Year
- IMRN N/A
- PHIO N/A
- Revenue Next Year
- IMRN N/A
- PHIO N/A
- P/E Ratio
- IMRN N/A
- PHIO N/A
- Revenue Growth
- IMRN 82.90
- PHIO N/A
- 52 Week Low
- IMRN $1.50
- PHIO $0.97
- 52 Week High
- IMRN $2.87
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- IMRN 58.70
- PHIO 50.19
- Support Level
- IMRN $1.68
- PHIO $2.11
- Resistance Level
- IMRN $1.94
- PHIO $2.30
- Average True Range (ATR)
- IMRN 0.09
- PHIO 0.21
- MACD
- IMRN 0.02
- PHIO -0.04
- Stochastic Oscillator
- IMRN 76.92
- PHIO 9.65
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.